Product Description: Tivumecirnon (FLX475) is an orally bioactive, selective CCR4 antagonist. Tivumecirnon can block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment, leading to enhanced antitumor activity. Tivumecirnon has antitumor activity on EBV+ NK/T cell lymphoma and non-small cell lung cancer (NSCLC) combined with Pembrolizumab (HY-P9902). Tivumecirnon is promising for research of broad range of tumor types[1][2][3][4].
Applications: Cancer-programmed cell death
Formula: C24H27Cl2F3N6O
References: [1]Hilary Plake BECK, et al. Chemokine receptor modulators and uses thereof. WO2018022992./[2]Adam Grant, et al. Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475. Cancer Res 15 March 2024; 84 (6_Supplement): 2485./[3]Tae Min Kim, et al. 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor[J]. 2023./[4]Dirk G. Brockstedt, et al., Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer. Journal of Clinical Oncology. 2023. 41, 2625-2625.
CAS Number: 2174938-78-2
Molecular Weight: 543.41
Compound Purity: 99.85
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: CCR
English
Deutsch
